RT Journal Article
SR Electronic
T1 Co-infection with SARS-COV-2 Omicron and Delta Variants Revealed by Genomic Surveillance
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.13.22270755
DO 10.1101/2022.02.13.22270755
A1 Rockett, Rebecca J
A1 Draper, Jenny
A1 Gall, Mailie
A1 Sim, Eby M
A1 Arnott, Alicia
A1 Agius, Jessica E
A1 Johnson-Mackinnon, Jessica
A1 Martinez, Elena
A1 Drew, Alexander P
A1 Lee, Clement
A1 Ngo, Christine
A1 Ramsperger, Marc
A1 Ginn, Andrew N
A1 Wang, Qinning
A1 Fennell, Michael
A1 Ko, Danny
A1 Huston, Linda
A1 Kairaitis, Lukas
A1 Holmes, Edward C
A1 O’Sullivan, Matthew N
A1 Chen, Sharon C-A
A1 Kok, Jen
A1 Dwyer, Dominic E
A1 Sintchenko, Vitali
YR 2022
UL http://medrxiv.org/content/early/2022/02/15/2022.02.13.22270755.abstract
AB We identified the co-infection of the SARS-CoV-2 Omicron and Delta variants in two epidemiologically unrelated patients with chronic kidney disease requiring haemodialysis. Both SARS-CoV-2 variants were co-circulating locally at the time of detection. Amplicon- and probe-based sequencing using short- and long-read technologies identified and quantified Omicron and Delta subpopulations in respiratory samples from the two patients. These findings highlight the importance of genomic surveillance in vulnerable populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Prevention Research Support Program funded by the New South Wales Ministry of Health and the NHMRC Centre for Research Excellence in Emerging Infectious Diseases (GNT1102962). The funders of this study had no role in the study design, data collection, data analysis and interpretation, or writing of the report. The corresponding author had full access to study data and final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical and governance approval for the study was granted by the Western Sydney Local Health District Human Research Ethics Committee 2020/ETH02426 and 2020/ETH00786)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe SARS-CoV-2 genome sequencing data is available (with human reads removed) in the National Center for Biotechnology Information (NCBI) GenBank (BioProject PRJNA633948).